Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Proteon Therapeutics, Inc. (NASDAQ: PRTO).

Full DD Report for PRTO

You must become a subscriber to view this report.


Recent News from (NASDAQ: PRTO)

Proteon Therapeutics to Present at Two Upcoming Investor Conferences
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present a corpora...
Source: GlobeNewswire
Date: August, 29 2018 08:00
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June ...
Source: GlobeNewswire
Date: August, 07 2018 08:00
Ra Medical Systems Aims For $86 Million IPO
Quick Take Ra Medical Systems ( RMED ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm provides laser therapies for a variety of dermatology and vascular diseases through the use of its proprietary products. RM...
Source: SeekingAlpha
Date: July, 30 2018 14:58
Reader Inquiry: Is Proteon Therapeutics Still A Buy?
Shares of Proteon Therapeutics (PRTO) have risen by 85% since I first brought the stock to readers' attention in June of last year. Year to date, the stock is in the green by over 30%. Chart Figure 1: PRTO daily advanced chart (Source: Finviz) Figure 2: PRTO 15-minute chart (S...
Source: SeekingAlpha
Date: June, 11 2018 12:20
Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient
Stock Monitor: BioCryst Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO ), all you need to do is sign up now by clicking the following link www.active-investors.com/reg...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:05
Proteon Therapeutics Announces First Quarter 2018 Financial Results
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March ...
Source: GlobeNewswire
Date: May, 09 2018 08:10
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
Partners extend existing contract for manufacture of vonapanitase to 2029 as ongoing Phase 3 trial nears completion Lonza Pharma & Biotech successfully scaled up a lab process at their Microbial facility in Visp, Switzerland, providing flexible solutions as Proteon moves toward possib...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended Decembe...
Source: GlobeNewswire
Date: March, 14 2018 08:00
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it has completed enrollment in PATENCY-2, t...
Source: GlobeNewswire
Date: March, 05 2018 17:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.302.402.402.3010,280
2018-05-212.152.152.152.0511,765
2018-05-182.102.102.102.0516,662
2018-05-172.102.002.102.0044,916
2018-05-162.102.052.102.0048,752

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-101,80017,16010.4895Cover
2018-12-073,39722,19815.3032Cover
2018-12-06101,8550.5391Cover
2018-12-045,3649,36657.2710Short
2018-11-301101,1589.4991Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRTO.


About Proteon Therapeutics, Inc. (NASDAQ: PRTO)

Logo for Proteon Therapeutics, Inc. (NASDAQ: PRTO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: PRTO)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Amendment to a previously filed 10-K
      Filing Type: 10-K/AFiling Source: edgar
      Filing Date: March, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: PRTO)

      Daily Technical Chart for (NASDAQ: PRTO)


      Stay tuned for daily updates and more on (NASDAQ: PRTO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: PRTO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRTO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PRTO and does not buy, sell, or trade any shares of PRTO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/